替米沙坦联合α-硫辛酸治疗2型糖尿病早期肾病  

作　　者：于湛[1] 

机构地区：[1]大连医科大学附属第一医院,116000

出　　处：《中国现代药物应用》2012年第9期21-23,共3页Chinese Journal of Modern Drug Application

摘　　要：目的研究替米沙坦联合α-硫辛酸治疗2型糖尿病早期肾病的临床疗效及观察其不良反应。方法 2型糖尿病早期肾病患者76例,随机分成替米沙坦联用硫辛酸组36例和替米沙坦组40例。替米沙坦组应用80 mg/d治疗,联合组应用缬沙坦80 mg/d,同时联用α-硫辛酸,观察两组疗效和不良反应,疗程2周。结果两组治疗后尿β2微球蛋白及UAER均有下降,联合治疗组较替米沙坦组下降更明显(P<0.01);治疗后两组间各指标比较,差异有统计学意义(P<0.05)。两组无明显不良反应。结论治疗糖尿病早期肾病,应用替米沙坦联合α-硫辛酸明显优于单用替米沙坦药物,二者有相互协同作用。Objective To investigate the efficacy and adverse effect of telmisartan combined with lipol- ic acid treatment on diabetic patients with early diabetic nephropathy. Methods 76 diabetic patients with early diabetic nephropathy enrolled. They were randomly assigned to two groups. 36 patients were treated with 80 mg per day telmisatan and the other 40 patients were treated with the same dose of telmisartan and lipolic acid. All patients were followed up with two weeks. The efficacy and adverse effect were observed. Results Two weeks later, the urinary 2-microglobulin and UAER decreased in both groups. But the urinary 2-microglobulin and UAER were significantly lower in patients treated with telmisartan and lipolic acid than that in patients treated with telmisartan （P 〈 0. 01）. The other outcome measurement were also different significantly between the two groups （P 〈 0. 05）. There was no any adverse effect in both groups. Conclusion The application of telmisar- tan combined α-lipoic acid is superior to telmisartan in diabetic patients with early diabetic nephropathy. Those two medicine have mutual synergies.

关 键 词：替米沙坦 硫辛酸 2型糖尿病 早期肾病 

分 类 号：R587.2[医药卫生—内分泌]